Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Primary IgA Nephropathy
NCT05824390Phase 4Unknown
- Sponsor
- Everest Medicines
- Start
- Jun 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in IgA nephropathy (IgAN) (2 arms), sponsored by Everest Medicines. Primary endpoint: Changes in proteinuria levels at 1 year. Status: unknown.
02
Drugs
rituximab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05824390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824390.